3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
https://www.zacks.com/commentary/2257822/3-generic-drug-stocks-to-watch-amid-challenging-market-prospects?cid=CS-ZC-FT-industry_outlook-2257822
Apr 18, 2024 - The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.
0
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/01/31/teva-pharmaceutical-industries-teva-q4-2023-earnin/?source=iedfolrf0000001
Jan 31, 2024 - TEVA earnings call for the period ending December 31, 2023.
0
Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4666377-teva-pharmaceutical-industries-teva-q4-2023-earnings-call-transcript?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ETCompany ParticipantsRichard Francis -...
0
Teva Pharmaceutical Non-GAAP EPS of $1.00 beats by $0.24, revenue of $4.46B beats by $450M
https://seekingalpha.com/news/4060531-teva-pharmaceutical-non-gaap-eps-of-1_00-beats-0_24-revenue-of-4_46b-beats-450m?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical reports strong Q4 earnings, exceeding expectations.
0
Teva hits 52-week high on outlook, API divestment
https://seekingalpha.com/news/4060755-teva-stock-hits-52-week-high-outlook?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical (TEVA) reached a new 52-week high after beating Q4 2023 forecasts and announcing plans to divest its API business. Read more here.
0
Teva earnings preview: Israeli drugmaker to report early Wednesday
https://seekingalpha.com/news/4060267-teva-earnings-preview-israeli-drugmaker-to-report-early-wednesday?source=feed_tag_israel
Jan 30, 2024 - Teva Pharmaceutical Industries (TEVA) is expected to report higher Q4 earnings before market open on Wednesday, with investors looking to see if the Israeli dru
0
Teva to divest API unit to focus on core business strengths
https://seekingalpha.com/news/4060502-teva-to-divest-api-unit-to-focus-on-core-business-strengths?source=feed_tag_israel
Jan 31, 2024 - Teva plans to divest its API business as part of its growth strategy, aiming to focus on core strengths and capitalize on opportunities in the global API...
0
TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up
https://www.zacks.com/stock/news/2219707/teva-q4-earnings-and-revenues-surpass-estimates-stock-up?cid=CS-ZC-FT-analyst_blog|earnings_article-2219707
Feb 01, 2024 - TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.
0
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel
Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
0
Teva upgraded at J.P. Morgan on upcoming catalysts
https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel
Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
0
<Page 2